It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Chondrosarcomas are primary cancers of cartilaginous tissue with highly contrasting prognoses. These tumors are defined by recurrent mutations in the IDH genes and other genetic alterations including inactivation of CDKN2A and COL2A1; however, these have no clinical value. Here we use multi-omics molecular profiles from a series of cartilage tumors and find an mRNA classification that identifies two subtypes of chondrosarcomas defined by a balance in tumor differentiation and cell cycle activation. The microRNA classification reveals the importance of the loss of expression of the 14q32 locus in defining the level of malignancy. Finally, DNA methylation is associated with IDH mutations. We can use the multi-omics classifications to predict outcome. We propose an mRNA-only classifier to reproduce the integrated multi-omics classification, and its application to relapsed tumor samples shows the progressive nature of the classification. Thus, it may be possible to use mRNA-based signatures to detect patients with high-risk chondrosarcomas.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Programme Cartes d’Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, Paris, France
2 Department of Pathology, CHU de Toulouse – Oncopole, Université de Toulouse, Toulouse, France
3 Plateforme de Génétique Moléculaire des Cancers, CHRU de Tours, Tours, France
4 Department of Biopathology, Centre Léon Bérard, Lyon, France; University of Lyon, Université Claude Bernard Lyon 1, CNRS 5286, INSERM U1052, Cancer Research Centre of Lyon, Lyon, France
5 Department of Pathology, CHU de Lille, Université de Lille, Lille, France
6 UMR1238 INSERM Université de Nantes, Sarcomes osseux et remodelage des tissus calcifiés, Faculté de médecine, NANTES, France
7 Department of Pathology, CHU de Nancy, Nancy, France
8 Department of Pathology, CHU de Marseille, Aix Marseille Université, INSERM, MMG, Marseille, France
9 Department of Orthopedic Surgery, Hôpital Pierre-Paul Riquet, CHU de Toulouse, Toulouse, France
10 UMR1238 INSERM Université de Nantes, Sarcomes osseux et remodelage des tissus calcifiés, Faculté de médecine, NANTES, France; Department of Orthopedic Surgery, CHRU de Tours, Université de Tours, Tours, France
11 Department of Orthopedic Surgery, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Sorbonne Paris Cité, Paris, France
12 Department of Surgery, Centre Léon Bérard, Lyon, France; Department of Orthopaedic Surgery, CHU Nantes, Nantes, France
13 Service de Pathologie, Hôpital Cochin, AP-HP, Université Paris Descartes, Paris, France
14 UMR1238 INSERM Université de Nantes, Sarcomes osseux et remodelage des tissus calcifiés, Faculté de médecine, NANTES, France; Department of Pathology, CHRU de Tours, Université de Tours, Tours, France